Skip to content
Clinical Trials – home

Futuremeds Łódź

Verified siteinfoFast reply

Poland Ul. Gruszowa 2, 91-363 Lodz, Poland

  • 19 trials recruiting
  • Psoriatic arthropathy · Arteriosclerosis · Sjogren's syndrome
  • Adult patients

About Specializations

Futuremeds Łódź in Lodz, Poland specialises in clinical trials of conditions such as Psoriatic arthropathy, Arteriosclerosis, Sjogren's syndrome, Hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Diseases and Immune System Phenomena

At Futuremeds Łódź, clinical research focuses on immune-related conditions and the ways the immune system behaves in disease. The main condition under study is Sjögren’s Syndrome With Moderate-toSevere Symptom State, with trials designed to better understand and assess new treatment options for patients living with persistent symptoms.

  • Evaluating a new therapy for Sjögren’s syndrome
  • Studying patient-reported symptoms in moderate-to-severe disease
  • Exploring how treatment may improve immune system-related outcomes

The research at this site is centered on improving care for people affected by autoimmune disease, with attention to symptom relief, treatment effectiveness, and overall patient experience.

Sjögren’s Syndrome Research

This site is also contributing to focused studies on Sjögren’s Syndrome, a chronic immune system disease that can cause significant discomfort and quality-of-life challenges. The trials are intended to evaluate whether a new therapy can help reduce symptoms and support better day-to-day functioning for patients with more severe symptom burden.

  • Assessing symptom improvement in Sjögren’s syndrome
  • Measuring patient-centered treatment benefit
  • Supporting development of better options for autoimmune disorders

With a small but specialized portfolio of studies, Futuremeds Łódź is helping advance research aimed at improving treatment choices for this uncommon but impactful condition.

Patient-Reported Outcomes in Autoimmune Research

The clinical trials at this health care site place strong emphasis on how patients feel and function, not just on disease markers. In particular, the research looks at patient-reported symptoms in Sjögren’s syndrome, helping determine whether investigational treatments may offer meaningful relief for people with moderate-to-severe symptoms.

  • Focusing on symptom burden in chronic immune disease
  • Testing whether treatment can improve daily well-being
  • Advancing care for immune system processes and related disorders

These studies reflect a broader effort to make clinical trial research more relevant to patients by examining real-world symptom change and treatment impact.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Gruszowa 291-363 LodzPoland
Recruiting now
19 trials
Conditions studied
41
Partner status
Verified site

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

68 clinical trials

Obesity+1

Recruiting

Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Diabetes mellitus+2

Recruiting

A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

COVID-19

Recruiting

A study testing molnupiravir in adults with COVID-19 who are not hospitalized and are at high risk for serious illness

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Molnupiravir
  • Sponsor:Merck Sharp & Dohme LLC

Cachexia

Recruiting

A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Visugromab
  • Sponsor:CatalYm GmbH

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Colorectal cancer+1

Recruiting

Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST GDNF FAMILY RECEPTOR ALPHA-LIKE
  • Sponsor:Ngm Biopharmaceuticals Inc.

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.